H.C. Wainwright analyst Joseph Pantginis says Fortress Biotech (FBIO) subsidiary Avenue Therapeutics (ATXI) announced this morning that its pivotal Phase 3 trial of IV tramadol achieved the primary endpoint in patients with moderate to moderately severe postoperative pain following bunionectomy surgery as well as important secondary endpoints. IV tramadol has the potential to be the first Schedule IV opioid in the U.S., and could be an important addition to pain treatments, Pantginis tells investors in a research note. The analyst currently projects $175M in peak sales, which he believes could be conservative based on the drug's profile. He reiterates a Buy rating on Fortress Biotech with an $11 price target.

Avenue Therapeutics announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on April 26, 2024 with a new CUSIP number of 05360L403. The ticker symbol for the Company's stock will remain "ATXI." The reverse stock split was approved on March 6, 2024 by Avenue's Board of Directors and stockholders representing approximately 56% of the voting power of Avenue's outstanding capital stock, with the authorization to determine the final ratio having been granted to the Company's Board of Directors.